What We Do
Building a pipeline of unique assets enabled by a world-leading platform for antibody discovery
HEPTAD
An unparalleled platform for the targeting GPCRs with antibodies
HEPTAD is DJS Antibodies' proprietary antibody discovery technology and delivers unprecedented success rates in the discovery of functional antibodies to GPCRs. It is built on a deep understanding of immunology and antibody production enabling us to discover functional antibodies to complex protein targets which have hitherto been intractable to drug discovery.
Asset Development
Creating value through the development of unique therapeutics
We use HEPTAD to discover antibodies against challenging GPCR targets where there is a strong commercial case for an antibody therapeutic. Lead antibodies discovered with HEPTAD are fed into our antibody development pipeline where our expert team works to accelerate their development through preclinical milestones and into the clinic.
Pipeline
We are building a unique pipeline of unique first-in-class antibody assets
Oncology
DJS-001
DJS-001 targets the tumour microenvironment to alleviate immunosuppression and enhance checkpoint inhibitor efficacy.
DJS has produced a panel of lead antibodies which out-perform existing antagonist molecules.
Chronic Kidney Disease
DJS-002
DJS-002 targets the key processes of fibrosis and filtration unit breakdown associated with CKD.
DJS has produced the first ever functional antibodies shown to antagonise signalling through this GPCR.
Rare Genetic Disease
DJS-003
DJS-003 hits a clinically validated target in a patient population where there is a high need for prophylactic treatments.
DJS has produced the first ever antibodies which bind to this receptor in its native conformation.
Our Team
Board of Directors
David Llewellyn
CEO
David completed a DPhil in Clinical Medicine at the University of Oxford as a Rhodes Scholar. He is an expert in the generation and characterisation of antibodies and has developed novel techniques for immune modulation.
Joe Illingworth
CSO
Joe has a background in biochemistry and immunology. He completed a DPhil and Post-doctoral work at the University of Oxford on antibody inducing vaccines. His expertise include inducing potent antibody responses to proteins which are difficult to express recombinantly.
Graeme Martin
Chairperson
Graeme has a background in pharmaceutical R&D with Glaxo Wellcome and Roche having seen multiple programmes through preclinical development and into the clinic. Most recently, he has led Takeda Ventures as CEO, and has been working with DJS for 3 years.
Andrew McLean
Director
Andy is a Principal at Oxford Sciences Innovation (OSI); an investment company formed to turn Oxford’s world beating science in world changing companies. Prior to joining OSI Andy trained as a physician and consulted in the pharmaceutical & biotech practice at McKinsey.
